Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

1.0K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.0K
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

1.4K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.4K
Glaucoma: Overview01:25

Glaucoma: Overview

1.5K
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
1.5K
Ophthalmic Drug Delivery Systems01:23

Ophthalmic Drug Delivery Systems

71
Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
71
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption01:22

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption

750
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
750
Direct-Acting Cholinergic Agonists: Therapeutic Uses01:11

Direct-Acting Cholinergic Agonists: Therapeutic Uses

1.9K
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
1.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Data Volume and the Need for Clinical Decision Support in Glaucoma Care.

Ophthalmology science·2026
Same author

Visual Field Progression in Glaucoma Patients With Delayed Follow-Up.

American journal of ophthalmology·2026
Same author

Evaluating Metrics Assessing Surgical Success in Patients Undergoing Cataract Surgery.

JAMA ophthalmology·2026
Same author

Toward an Era of Oculomics: Association between Baseline Diabetic Retinopathy Severity and Mortality Risk in a SOURCE Consortium Cohort.

Ophthalmology·2026
Same author

Linking multicenter electronic health records with socioeconomic data to examine receipt of standard versus premium intraocular lenses.

AJO international·2026
Same author

Improving Fairness and Mitigating Bias in Multicenter Electronic Health Records Models to Predict Glaucoma Outcomes.

Ophthalmology science·2026

Related Experiment Video

Updated: Feb 23, 2026

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents
10:10

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Published on: February 15, 2022

2.0K

Changing Initial Glaucoma Medical Therapy Increases Healthcare Resource Utilization.

Matthew G J Trese1,2, Andrew W Lewis1,3, Taylor S Blachley1

  • 11 Department of Ophthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan , Ann Arbor, Michigan.

Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics
|August 31, 2017
PubMed
Summary

Changing initial glaucoma therapy is common, especially for those on beta blockers. Patients who switch treatments face higher costs and more frequent visits, highlighting the need for optimized initial strategies.

Keywords:
claims datahealthcare related costsocular hypertensionopen-angle glaucomaprostaglandin analogstopical beta blocker

More Related Videos

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
08:30

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Published on: March 12, 2016

13.7K
Laser Capture Microdissection of Highly Pure Trabecular Meshwork from Mouse Eyes for Gene Expression Analysis
13:47

Laser Capture Microdissection of Highly Pure Trabecular Meshwork from Mouse Eyes for Gene Expression Analysis

Published on: June 3, 2018

9.9K

Related Experiment Videos

Last Updated: Feb 23, 2026

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents
10:10

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Published on: February 15, 2022

2.0K
Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
08:30

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Published on: March 12, 2016

13.7K
Laser Capture Microdissection of Highly Pure Trabecular Meshwork from Mouse Eyes for Gene Expression Analysis
13:47

Laser Capture Microdissection of Highly Pure Trabecular Meshwork from Mouse Eyes for Gene Expression Analysis

Published on: June 3, 2018

9.9K

Area of Science:

  • Ophthalmology
  • Health Economics

Background:

  • Open-angle glaucoma (OAG) and ocular hypertension (OHT) are common conditions requiring long-term management.
  • Initial therapeutic choices for OAG/OHT can significantly influence patient outcomes and healthcare resource utilization.

Purpose of the Study:

  • To investigate the frequency and economic implications of altering initial glaucoma treatments.
  • To analyze factors influencing treatment changes in newly diagnosed OAG/OHT patients.

Main Methods:

  • Retrospective longitudinal cohort study of 15,019 patients diagnosed with OAG or OHT between 2001-2012.
  • Analysis of claims data to track therapy changes (beta blockers vs. prostaglandin analogs) within 12 months of initial prescription.
  • Examination of healthcare resource utilization and associated costs.

Main Results:

  • 80.9% of patients initiated on prostaglandin analogs (PGAs) versus 19.1% on beta blockers (BBs).
  • Treatment changes occurred in 29.2% of PGA users and 39.5% of BB users within 12 months.
  • Patients on BBs had higher odds of therapy change (OR 0.61) and incurred greater healthcare costs and office visits compared to those on PGAs.

Conclusions:

  • Initial ocular hypotensive therapy modification is frequent in OAG/OHT management.
  • Treatment changes are associated with increased monitoring needs and higher healthcare expenditures.
  • Optimizing initial therapy selection may improve patient outcomes and reduce costs.